机译:聚乙二醇化脂质体阿霉素(JNS002)在日本米勒癌(上皮性卵巢癌,输卵管原发癌,腹膜癌)患者中的铂类化学疗法的II期临床试验:日本妇科肿瘤学的II期研究组
Department of Medical Oncology National Cancer Center Tokyo;
Department of Obstetrics and Gynecology Kurume University School of Medicine Kurume Fukuoka;
Department of Gynecologic Oncology Aichi Cancer Center Hospital Nagoya;
Department of Obstetrics and Gynecology Kagoshima City Hospital Kagoshima;
Department of Obstetrics and Gynecology School of Medicine Keio University Tokyo;
Department of Obstetrics and Gynecology Niigata University Graduate School of Medical and Dental Science Niigata;
Department of Obstetrics and Gynecology Osaka City General Hospital Osaka;
Department of Gynecologic Oncology Osaka Medical Center for Cancer and Cardiovascular Diseases Osaka;
Department of Gynecologic Oncology National Hospital Organization Kure Medical Center and Chugoku Cancer Center Kure Hiroshima;
Department of Obstetrics and Gynecology Iwate Medical University School of Medicine Morioka;
Department of Obstetrics and Gynecology Tottori University School of Medicine Yonago Tottori;
Department of Obstetrics and Gynecology Kawasaki Medical University Kurashiki Okayama;
Department of Obstetrics and Gynecology Jikei University School of Medicine Tokyo;
Clinical Research Development Department Janssen Pharmaceutical K.K. Tokyo;
Kinki University School of Medicine Osakasayama Osaka Japan;
机译:聚乙二醇化阿霉素(JNS002)的二期临床试验在患有铂类药物治疗史的苗勒氏癌(上皮性卵巢癌,输卵管原发性癌,腹膜癌)的日本患者中
机译:他莫昔芬与沙利度胺在仅有一线生化复发的上皮性卵巢癌,输卵管癌或原发性腹膜癌的女性中,对一线铂/紫杉类化学疗法产生完全反应并评估血清血管内皮生长因子(VEGF)后,进行了一项随机的III期临床试验:妇科肿瘤小组研究。
机译:聚乙二醇脂质体阿霉素和卡铂在日本患有铂敏感型复发性卵巢癌,输卵管癌或原发性腹膜癌患者的II期临床试验
机译:Sorafenib之外的肝细胞癌中的分子疗法:III期试验失败的课程和新型靶标
机译:聚乙二醇化脂质体阿霉素(JNS002)在日本米勒癌(上皮性卵巢癌输卵管原发癌腹膜癌)患者中的铂类化学疗法的II期临床试验:日本妇科肿瘤学的II期研究组
机译:聚乙二醇化脂质体阿霉素(JNS002)在日本米勒癌(上皮性卵巢癌,输卵管原发癌,腹膜癌)患者中的铂类化学疗法的II期临床试验:日本妇科肿瘤学的II期研究组